Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06463340 · ClinicalTrials.gov registry record · Phase 1

Study of SGR-3515 In Participants With Advanced Solid Tumors.

A Phase 1 study of Advanced Solid Tumor, sponsored by Schrödinger.

Recruiting
Registry status
Phase 1
Development phase
52
Enrollment target
14
Study locations

NCT06463340: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Schrödinger.

NCT06463340 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Schrödinger. The registered enrollment target is 52 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06463340, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Schrödinger.

RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

Primary Outcome

Incidence and severity of adverse events (AEs) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0 and changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs); and dose interruptions, dose reductions, dose delays and study drug discontinuation due to AEs.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG SGR-3515

Study Locations (14)

Michigan

  • University of Michigan - Ann Arbor
  • Karmanos Cancer Institute - Detroit

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Ohio State University - Columbus

Tennessee

  • Sarah Cannon Research Institute - Nashville
  • Vanderbilt-Ingram Cancer Center/Henry-Joyce Cancer Clinic - Nashville

Connecticut

  • Yale University, Yale Cancer Center - New Haven

Illinois

  • Northwestern University - Chicago

New York

  • Icahn School of Medicine at Mount Sinai - New York

North Carolina

  • Levine Cancer Institute - Charlotte

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-06-18
Est. Completion 2026-12-31
Phase Phase 1
Schrödinger

3 total trials

What NCT06463340 shows while recruiting

NCT06463340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which SGR-3515 is the first listed.

NCT06463340 lists 14 locations in 11 states (Michigan, Ohio, Tennessee).

Frequently Asked Questions

What is clinical trial NCT06463340 about?

NCT06463340 is a clinical study titled "Study of SGR-3515 In Participants With Advanced Solid Tumors.". The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

What is the current status of trial NCT06463340?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-06-18. Estimated completion is 2026-12-31.

What conditions does trial NCT06463340 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06463340?

The interventions under investigation include: SGR-3515 (DRUG).

Who is sponsoring clinical trial NCT06463340?

This trial is sponsored by Schrödinger, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06463340 being conducted?

This trial has 14 study locations across Connecticut, Illinois, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06463340's enrollment target sits among peer trials

52 155th of 189 higher than 32 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06463340

Source: ClinicalTrials.gov NCT06463340, the US trial registry maintained by the National Library of Medicine. NCT06463340 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.